Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 6, 2024, in New York City.
Key details:
- President and CEO Rob Spignesi and CFO Sean Wirtjes will participate
- 35-minute Q&A session with the host analyst
- Session starts at 7:00 a.m. Eastern Time
- Live webcast available on the company's investor relations website
- Archived webcast will be accessible for replay after the event
This conference provides an opportunity for Rapid Micro Biosystems to showcase its innovative solutions and engage with industry professionals and investors.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), una società tecnologica nel settore delle scienze della vita specializzata in soluzioni di automazione per la produzione di prodotti sanitari, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. L'evento si svolgerà il 6 settembre 2024, a New York.
Dettagli chiave:
- Il Presidente e CEO Rob Spignesi e il CFO Sean Wirtjes parteciperanno
- Sessione di domande e risposte di 35 minuti con l'analista ospite
- La sessione inizia alle 7:00 ora orientale
- Webcast in diretta disponibile sul sito delle relazioni con gli investitori della società
- Webcast registrato sarà accessibile per la riproduzione dopo l'evento
Questa conferenza offre a Rapid Micro Biosystems l'opportunità di mostrare le proprie soluzioni innovative e interagire con professionisti e investitori del settore.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), una empresa de tecnología en ciencias de la vida especializada en soluciones de automatización para la fabricación de productos de salud, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El evento está programado para el 6 de septiembre de 2024, en la ciudad de Nueva York.
Detalles clave:
- El Presidente y CEO Rob Spignesi y el CFO Sean Wirtjes participarán
- Sesión de preguntas y respuestas de 35 minutos con el analista anfitrión
- La sesión comienza a las 7:00 a.m. hora del Este
- Transmisión en vivo disponible en el sitio web de relaciones con inversores de la empresa
- Transmisión archivada será accesible para reproducción después del evento
Esta conferencia brinda a Rapid Micro Biosystems la oportunidad de mostrar sus soluciones innovadoras y interactuar con profesionales e inversores de la industria.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID)는 의료 제품 제조를 위한 자동화 솔루션을 전문으로 하는 생명 과학 기술 회사로, 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여할 계획을 발표했습니다. 이 행사는 2024년 9월 6일 뉴욕에서 예정되어 있습니다.
주요 세부사항:
- 사장 겸 CEO인 Rob Spignesi와 CFO인 Sean Wirtjes가 참석합니다.
- 주최 애널리스트와 35분간의 질의응답 세션
- 세션은 동부 시간 기준으로 오전 7시에 시작됩니다.
- 회사의 투자자 관계 웹사이트에서 라이브 웹캐스트가 제공됩니다.
- 행사 후에는 다시 볼 수 있도록 웹캐스트가 아카이브됩니다.
이번 회의는 Rapid Micro Biosystems가 혁신적인 솔루션을 선보이고 업계 전문가 및 투자자와 소통할 수 있는 기회를 제공합니다.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), une entreprise technologique spécialisée dans les sciences de la vie, axée sur des solutions d'automatisation pour la fabrication de produits de santé, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Cet événement est prévu pour le 6 septembre 2024, à New York.
Détails clés :
- Le Président et PDG Rob Spignesi et le CFO Sean Wirtjes participeront
- Session de questions-réponses de 35 minutes avec l'analyste hôte
- La session commence à 7h00, heure de l'Est
- Webdiffusion en direct disponible sur le site web des relations avec les investisseurs de l'entreprise
- Webdiffusion archivée sera accessible pour rediffusion après l'événement
Cette conférence offre à Rapid Micro Biosystems l'opportunité de présenter ses solutions innovantes et d'interagir avec des professionnels et des investisseurs du secteur.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), ein Unternehmen für Life Sciences-Technologie, das sich auf Automatisierungslösungen für die Herstellung von Gesundheitsprodukten spezialisiert hat, hat seine Teilnahme an der 22. Jahrestagung für Globale Gesundheit von Morgan Stanley angekündigt. Die Veranstaltung findet am 6. September 2024 in New York City statt.
Wichtige Details:
- Präsident und CEO Rob Spignesi sowie CFO Sean Wirtjes werden teilnehmen
- 35-minütige Fragerunde mit dem Gastgeberanalysten
- Die Sitzung beginnt um 7:00 Uhr Eastern Time
- Live-Webcast auf der Investor-Relations-Website des Unternehmens verfügbar
- Archiv-Webcast wird nach der Veranstaltung zur Wiederholung bereitstehen
Diese Konferenz bietet Rapid Micro Biosystems die Möglichkeit, seine innovativen Lösungen zu präsentieren und mit Branchenprofis und Investoren in Kontakt zu treten.
- None.
- None.
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City.
Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 35-minute question-and-answer session with the host analyst at 7:00 a.m. Eastern Time. A live webcast of the session will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
FAQ
When is Rapid Micro Biosystems (RPID) participating in the Morgan Stanley Healthcare Conference?
Who will represent Rapid Micro Biosystems (RPID) at the Morgan Stanley Healthcare Conference?
What time is Rapid Micro Biosystems' (RPID) Q&A session at the Morgan Stanley conference?
How can investors access the webcast of Rapid Micro Biosystems' (RPID) conference session?
Will the webcast of Rapid Micro Biosystems' (RPID) Morgan Stanley conference session be available for replay?
